Source author record

Christian L. Althaus

Christian L. Althaus appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Populations and Evolution Methodology

Catalog footprint

What is connected

3works

2topics

4close collaborators

Actions

Connect this record

Open graph Browse works

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

preprint2020arXiv

COVID-19 infectivity profile correction

The infectivity profile of an individual with COVID-19 is attributed to the paper Temporal dynamics in viral shedding and transmissibility of COVID-19 by He et al., published in Nature Medicine in April 2020. However, the analysis within this paper contains a mistake such that the published infectivity profile is incorrect and the conclusion that infectiousness begins 2.3 days before symptom onset is no longer supported. In this document we discuss the error and compute the correct infectivity profile. We also establish confidence intervals on this profile, quantify the difference between the published and the corrected profiles, and discuss an issue of normalisation when fitting serial interval data. This infectivity profile plays a central role in policy and decision making, thus it is crucial that this issue is corrected with the utmost urgency to prevent the propagation of this error into further studies and policies. We hope that this preprint will reach all researchers and policy makers who are using the incorrect infectivity profile to inform their work.

preprint2014arXiv

Estimating the reproduction number of Ebola virus (EBOV) during the 2014 outbreak in West Africa

The 2014 Ebola virus (EBOV) outbreak in West Africa is the largest outbreak of the genus Ebolavirus to date. To better understand the spread of infection in the affected countries, it is crucial to know the number of secondary cases generated by an infected index case in the absence and presence of control measures, i.e., the basic and effective reproduction number. In this study, I describe the EBOV epidemic using an SEIR (susceptible-exposed-infectious-recovered) model and fit the model to the most recent reported data of infected cases and deaths in Guinea, Sierra Leone and Liberia. The maximum likelihood estimates of the basic reproduction number are 1.51 (95% confidence interval [CI]: 1.50-1.52) for Guinea, 2.53 (95% CI: 2.41-2.67) for Sierra Leone and 1.59 (95% CI: 1.57-1.60) for Liberia. The model indicates that in Guinea and Sierra Leone the effective reproduction number might have dropped to around unity by the end of May and July 2014, respectively. In Liberia, however, the model estimates no decline in the effective reproduction number by end-August 2014. This suggests that control efforts in Liberia need to be improved substantially in order to stop the current outbreak.

preprint2013arXiv

Re-infection by untreated partners of people treated for Chlamydia trachomatis and Neisseria gonorrhoeae: mathematical modelling study

Objectives: Re-infection after treatment for Chlamydia trachomatis or Neisseria gonorrhoeae reduces the effect of control interventions. We explored the impact of delays in partner treatment on the expected probability of re-infection of index cases using a mathematical model. Methods: We used previously reported parameter distributions to calculate the probability that index cases would be re-infected by their untreated partners. We then assumed different delays between index case and partner treatment to calculate the probabilities of re-infection. Results: In the absence of partner treatment, the medians of the expected re-infection probabilities are 19.4% (interquartile range (IQR) 9.2-31.6%) for chlamydia and 12.5% (IQR 5.6-22.2%) for gonorrhoea. If all current partners receive treatment three days after the index case, the expected re-infection probabilities are 4.2% (IQR 2.1-6.9%) for chlamydia and 5.5% (IQR 2.6-9.5%) for gonorrhoea. Conclusions: Quicker partner referral and treatment can substantially reduce re-infection rates for chlamydia and gonorrhoea. The formula we used to calculate re-infection rates can be used to inform the design of randomised controlled trials of novel partner notification technologies like accelerated partner therapy.